Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 7Myeloid 4Genitourinary 4Gastrointestinal 4CNS 4Sarcoma 3Plasma cell 3

Conditions

Multiple Myeloma 3Lymphoma 3

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Nuclear Medicine Department, Hospital × Plasma cell × Clear all
NCT06357988 2026-05-28

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT06385483 2026-05-28

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
19 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT06390826 2026-05-28

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
10 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡